amicus therapeutics inc (FOLD) Key Developments
James N. Topper Not to Seek for Re-Election to the Board of Amicus Therapeutics
Apr 13 15
On April 9, 2015, James N. Topper, M.D., Ph.D. informed the board of directors of Amicus Therapeutics, Inc. that he will not seek re-election to the Board when his term expires at the company's upcoming 2015 Annual Meeting of Stockholders.
Amicus Therapeutics, Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2014; Provides Cash Spend Guidance for the Year of 2015
Mar 3 15
Amicus Therapeutics, Inc. reported unaudited consolidated earnings results for the fourth quarter and year ended December 31, 2014. For the quarter, the company reported loss from operations of $21.997 million compared to $15.790 million a year ago. Loss before tax was $22.332 million compared to $15.749 million a year ago. Net loss attributable to common stockholders was $21.219 million or $0.24 per basic and diluted share compared to $12.237 million or $0.22 per basic and diluted share a year ago.
For the year, the company reported total revenue of $1.224 million compared to $0.363 million a year ago. Loss from operations was $68.701 million compared to $64.181 million a year ago. Loss before tax was $70.039 million compared to $63.145 million a year ago. Net loss attributable to common stockholders was $68.926 million or $0.93 per basic and diluted share compared to $59.633 million or $1.16 per basic and diluted share a year ago. Net cash spend was $53.2 million. The narrower net loss per share versus the year-ago period is attributed to an increase in the shares outstanding as a result of ATM and follow-on public offerings.
The company expects full-year 2015 net cash spend between $73 million and $83 million.
Amicus Therapeutics Seeks Acquisitions
Mar 3 15
Amicus Therapeutics, Inc. (NasdaqGM:FOLD) stated in its Form S-3 filed on March 3, 2015 that, except as otherwise provided in the applicable prospectus supplement relating to a specific offering, they intend to use the net proceeds from the sale of securities by us under this prospectus for general corporate purposes, which may include working capital, capital expenditures, research and development expenditures, clinical trial expenditures, commercial expenditures, acquisitions of new technologies or businesses, and investments. Additional information on the use of net proceeds from the sale of securities under this prospectus may be set forth in the prospectus supplement relating to the specific offering.
Amicus Therapeutics, Inc. to Report Fiscal Year 2014 Results on Mar 03, 2015
Mar 1 15
Amicus Therapeutics, Inc. announced that they will report fiscal year 2014 results on Mar 03, 2015
Amicus Therapeutics, Inc. Announces Resignation of James Barrett from the Board of Directors, Effective March 1, 2015
Feb 27 15
On February 25, 2015, M. James Barrett informed Amicus Therapeutics, Inc. that he has chosen to resign from the Board of Directors effective March 1, 2015.